CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02499081
NCT02499081Phase 2Completed
CompareCT.gov

Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients

University of Arkansas·interventional·Posted Jul 15, 2015·Updated Jun 11, 2021

In Brief

A Phase 2 clinical trial evaluating Ixazomib for Multiple Myeloma. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effect of Ixazomib on inducing osteoblast activation as measured by bone markers and imaging in patients with relapsed/refractory myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 15, 2015
Enrollment StartSep 1, 2015
Primary CompletionMay 17, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.0 years ago

Interventions

Ixazomibdrug